Zytoprotec Completes Phase I/II Trial of Novel Dialysate
“This randomized cross-over trial has shown that PD-protec™ is safe and well-tolerated”, said Dr. Christoph Aufricht, Chief Scientific Officer of Zytoprotec. “The trial was also designed to provide biological material to be analyzed for indicators of efficacy. While we are currently processing the samples, we see first hints that PD-protec™ may improve survival of abdominal cells in peritoneal dialysis.”
“I am very pleased that Zytoprotec has reached this important clinical milestone for its lead product”, said Peter C. Weilguni, Chief Executive Officer of the Company. “Our development team has demonstrated great discipline and I am confident that we will be able to initiate the Phase II trial with PD-protec™ in autumn this year. We are currently preparing for the financing of this trial, and are in advanced negotiations with a venture fund closely linked to a global pharmaceutical company. “
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.